Lung cancer is one of the most common cancer in the world. In 2018, there were over 2
million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer …

BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway.
Concomitant mutations in both KRAS and BRAF genes have been identified in non-small …

KRAS is the most frequent oncogene in non-small cell lung cancer (NSCLC), a molecular
subset characterized by historical disappointments in targeted treatment approaches such …

Non-small cell lung carcinoma (NSCLC) comprises 80%–85% of lung cancer cases. EGFR
is involved in several cancer developments, including NSCLC. The EGFR pathway …

Introduction Several targetable genetic alterations have been identified in non-small cell
lung cancers (NSCLC) and drugs targeting these alterations have been approved for the …

Introduction: Lung cancer is the leading cause of cancer-related mortality globally. Despite
recent advances with personalized therapies and immunotherapy, the prognosis remains …

Abstract Purpose of Review Although the recent development of direct KRASG12C inhibitors
(G12Ci) has improved outcomes in KRAS mutant cancers, responses occur only in a fraction …

Aberrations in rat sarcoma (RAS) viral oncogene are the most prevalent and best-known
genetic alterations identified in human cancers. Indeed, RAS drives tumorigenesis as one of …

KRAS is the most frequently mutated oncogene identified in human cancers. Despite the
numerous efforts to develop effective specific inhibitors against KRAS, this molecule has …

Increased abundance of polo-like kinase 1 (PLK1) is observed in various tumor types,
particularly in lung adenocarcinoma (LUAD). Here, we found that PLK1 accelerated the …